Evonik Industries will implement price increases for its pharmaceutical excipients and medical device polymers sold under the EUDRAGIT® and RESOMER® brands. Depending on the product grade, the sales price increase will be up to 12 percent and become effective for shipments after November 1, 2014.
This price adjustment is necessary to maintain the high level of service and quality Evonik customers are accustomed to.
Evonik is committed to investments that enhance the quality and availability of supplies and services which support its customers’ growth. The continuous expansion of the global lab and manufacturing resources exemplifies this commitment.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.7 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.